

# THE CLINICAL PROTEOMIC TUMOR ANALYSIS CONSORTIUM STEERING COMMITTEE MEETING

#### <SCIENTIFIC & PROGRAMMATIC UPDATES>

### WEDNESDAY SEPTEMBER 23, 2020

#### A VIRTUAL CLOSED MEETING

The CPTAC Steering Committee Meeting will begin at 10:00 a.m. ET and will conclude at 5:30 p.m. ET

#### **AGENDA**

10:00 a.m.	Session I: Tumor Characterization Program
	(20 min Presentation + 5 min Q&A)  Moderator: Ana Robles, Ph.D., NCI
10:00 a.m. – 10:25 a.m.	Proteogenomic Analysis of Lung Squamous Cell Carcinoma, Discovery Samples Flagship Manuscript/ Progress report Shankha Satpathy, Ph.D., Broad institute
10:25 a.m. – 10:50 a.m.	Proteogenomic Analysis of Pancreatic Ductal Adenocarcinoma, Discovery Samples Flagship Manuscript/ Progress report Hui Zhang, Ph.D., Johns Hopkins School of Medicine Bing Zhang, Ph.D., Baylor College of Medicine
10:50 a.m. – 11:15 a.m.	Proteogenomic and Metabolomic Characterization of Human Glioblastoma Tao Liu, Ph.D., Pacific Northwest National Laboratory
11:15 a.m.	Session II: Proteogenomic Translational Program
	(20 min Presentation + 5 min Q&A)  Moderator: Mehdi Mesri, Ph.D., NCI
11:15 a.m. – 11:40 a.m.	Microscaled Proteogenomics of TNBC Clinical Trial Breast Cancer Biospecimens Meenakshi Anurag., Ph.D., Baylor College of Medicine
11:40 a.m. – 12:05 p.m.	Mechanism of Platinum Resistance in Ovarian Cancer  Amanda Paulovich, M.D., Ph.D., Fred Hutchinson Cancer Research Center  Michael Birrer, M.D., Ph.D., University of Arkansas for Medical Sciences

12:05 p.m. – 12:45 p.m. Lunch & poster viewing

12:45 p.m.	Session III: Tumor Characterization Program (Supporting Activities)
	Moderator: Tara Hiltke, Ph.D., NCI
12:45 p.m. – 1:30 p.m.	CPTAC Pan-cancer Studies Status: Implementation, Requirements, Open Discussion Ana Robles, Ph.D., NCI Li Ding, Ph.D. Washington University in St. Louis
1:30 p.m. – 1:50 p.m.	Progress on Pan-cancer Stemness as Hallmark of Oncogenic Progression  Maciej Wiznerowicz, M.D., Ph.D., International Institute for Molecular Oncology,  Poland
1:50 p.m. – 2:10 p.m.	Overview of Single Nuclei Analyses Across Multiple CPTAC Cancers Li Ding, Ph.D. Washington University in St. Louis
2:10 p.m. – 2:30 p.m.	Initial Assessment of CPTAC DIA Datasets Steve Stein, Ph.D., National Institute of Standards and Technology
2:30 p.m. – 2:45 p.m.	Break

## 2:45 p.m. Session IV: Tumor Characterization Program (Pilot projects)

## PTRCs and PCCs will provide summaries/outcomes of their all Pilot Projects

	(15 min Presentation)  Moderator: Eunkyung An, Ph.D., NCI
2:45 p.m. – 3:00 p.m.	BCM/Broad Institute Breast Cancer PTRC
3:00 p.m. – 3:15 p.m.	FHCRC/UAMS Ovarian Cancer PTRC
3:15 p.m. – 3:30 p.m.	PNNL/OHSU AML PTRC
3:30 p.m. – 3:45 p.m.	PNNL PCC
3:45 p.m. – 4:00 p.m.	JHU PCC
4:00 p.m. – 4:15 p.m.	Broad Institute PCC

**Break** 

4:15 p.m. – 4:30 p.m.



4:30 p.m.	Session V: Tumor Characterization Program (Disease Working Groups, Status
	Prior to the meeting, the Disease Working Group chair(s), in coordination with their teams, will summarize/integrate a status report (main tasks/action items/timelines), and create a short PPT. slide deck for presentation to the consortium
	(20 min Presentation)  Moderator: Mehdi Mesri, Ph.D., NCI
4:30 p.m. – 4:50 p.m.	Head & Neck, Pancreatic, and Kidney teams Joint JHU PCC and Associated PGDAC (Baylor)
	Hui Zhang, Ph.D., Bing Zhang, Ph.D.
4:50 p.m. – 5:10 p.m.	GBM, AYA, and Endometrial teams Joint PNNL PCC and Associated PGDACs (NYU/WashU/BYU, Mt. Sinai, BCM)
	Tao Liu, Ph.D., Li Ding, Ph.D., Pei Wang, Ph.D.
5:10 p.m. – 5:30 p.m.	Lung Adenocarcinoma and Lung Squamous Cell Carcinoma teams Joint Broad PCC and Associated PGDACs (Broad & UMich)
	D.R. Mani, Ph.D., Alexey Nesvizhskii, Ph.D.
5:30 p.m.	Adjourn

